Form 4: BridgeBio Pharma Director Frank McCormick Receives Significant Equity Awards

BridgeBio Pharma, Inc. Director Frank McCormick was granted 6,589 restricted stock units and 8,425 stock options, vesting over three years, as part of his compensation package.

Summary

• Frank McCormick, a Director of BridgeBio Pharma, Inc. (BBIO), was granted equity awards on June 20, 2025.
• The awards consist of 6,589 Restricted Stock Units (RSUs) and 8,425 stock options.
• Each RSU represents a contingent right to receive one share of BridgeBio Pharma's Common Stock.
• The stock options have an exercise price of $41.73 and are set to expire on June 19, 2035.
• Both the RSUs and stock options will vest in equal one-third increments annually, commencing after June 20, 2025, with full vesting by June 20, 2028, contingent upon Mr. McCormick's continued service on the company's board of directors.
• Following these transactions, Mr. McCormick directly beneficially owns 83,275 shares of Common Stock and 8,425 stock options.
• An additional 979,979 shares of Common Stock are indirectly beneficially owned by the Francis P. McCormick Rev Trust U/A DTD 1/27/2017.
• The transaction was executed pursuant to a Rule 10b5-1(c) plan.

Sentiment

Score: 6

Explanation: The document reports a routine equity grant to a director, which is a positive for aligning interests but does not indicate significant new positive or negative developments for the company's operations or financial health beyond standard compensation practices.

Positives

• The grant of equity awards aligns the director's financial interests with the long-term performance and shareholder value of BridgeBio Pharma.
• The multi-year vesting schedule incentivizes and encourages the director's continued service and commitment to the company's strategic objectives.

Negatives

• The future issuance of shares upon RSU vesting and stock option exercise will result in a degree of dilution for existing shareholders, which is a common aspect of equity compensation plans.

Risks

• The ultimate value realized from the granted equity awards is directly dependent on the future stock price performance of BridgeBio Pharma, which is subject to market volatility and company-specific factors.
• The full vesting of both the RSUs and stock options is contingent upon Mr. McCormick's continued service on the Issuer's board of directors until June 20, 2028.

Future Outlook

The vesting schedule for the granted equity awards extends through June 20, 2028, indicating an expectation of continued service from the director and a long-term incentive structure designed to align his interests with the company's future performance.

Industry Context

This Form 4 filing reflects a standard practice within the biotechnology and pharmaceutical industry, where equity compensation, including restricted stock units and stock options, is a common tool used to incentivize and retain key directors and executives, thereby aligning their interests with the long-term strategic goals and performance of the company.

Related Party Transactions

• The grant of restricted stock units and stock options to Frank McCormick, a director of BridgeBio Pharma, Inc., constitutes a related party transaction as it involves compensation from the company to a member of its board.

Stakeholder Impact

• Shareholders: The equity grants align the director's interests with shareholder value, but also represent potential future dilution upon vesting and exercise.
• Employees: No direct impact on general employees is mentioned.
• Customers: No direct impact on customers is mentioned.
• Suppliers: No direct impact on suppliers is mentioned.
• Creditors: No direct impact on creditors is mentioned.

Next Steps

• One-third of the granted RSUs will vest annually after June 20, 2025.
• One-third of the granted stock options will vest annually after June 20, 2025.
• Full vesting of both RSUs and stock options is expected by June 20, 2028, contingent on continued board service.
• The stock options will expire on June 19, 2035.

Key Dates

Keywords

BridgeBio Pharma, BBIO, SEC Form 4, Insider Transaction, Equity Grant, Restricted Stock Units, RSUs, Stock Options, Director Compensation, Frank McCormick, 10b5-1 Plan